Literature DB >> 2502310

Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.

A S Chong1, A Aleksijevic, P Scuderi, E M Hersh, W J Grimes.   

Abstract

Lymphokine-activated killer (LAK) cells are generated by the culture of peripheral blood lymphocytes with interleukin-2 (IL-2). A variety of cells, including T-lymphocytes and natural killer (NK) cells, can be activated by IL-2 to exhibit the ability to kill multiple tumor and "modified-self" targets. Recent reports indicate that culture conditions can determine the phenotype of cells expressing LAK activity. Using limiting dilution techniques, we first generated cloned LAK cells with three culture conditions: autologous human serum (AHS) + IL-2; AHS + IL-2 + 0.1 micrograms/ml phytohemagglutinin and fetal bovine serum and IL-2. We determined that all but one of the 47 LAK cell clones generated with the three culture conditions were CD3+ and T-cell like; one NK-like clone was observed. Clones that were cytotoxic for one target could generally kill multiple targets, and the absence of phytohemagglutinin did not significantly affect the ability of the LAK cell clones to kill multiple targets. The presence of phytohemagglutinin was, however, necessary for the long-term maintenance of proliferation and cytotoxic activity of the LAK cell clones. The mechanism by which LAK cells kill tumor targets is not known. We here demonstrate that LAK cells and LAK cell clones can produce interferon-gamma and tumor necrosis factor (TNF) when stimulated with an erythroleukemia cell, K562. Five of the six CD3+, LAK cell clones tested could be stimulated by K562 cells to produce both interferon-gamma and TNF. However, the ability of the cloned LAK cells to kill K562 cells, as measured in a 4-h 51Cr-release assay, did not correlate with their ability to produce these cytokines. Furthermore, specific antibodies that neutralize the cytotoxic activity of interferon-gamma and TNF did not inhibit killing of K562 cells by LAK cells as measured with a 4-h cytotoxic assay. The cytostatic and cytotoxic activities of interferon-gamma and TNF for tumor cells are well documented, but these cytolytic activities are slower acting and exhibit their maximum effect after 48-96 h. We here propose that LAK cells kill tumor targets by a combination of cell-to-cell-mediated killing and by the release of slower acting cytostatic/cytotoxic cytokines that can inhibit the growth of tumors some distance from the effector cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502310     DOI: 10.1007/bf00199215

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  39 in total

1.  Surface markers of human lymphokine-activated killer cells and their precursors. Analysis at the population and clonal level.

Authors:  S Ferrini; L Moretta; G Pantaleo; A Moretta
Journal:  Int J Cancer       Date:  1987-01-15       Impact factor: 7.396

Review 2.  Status and potential of interleukin-2 for the treatment of neoplastic disease.

Authors:  P M Sondel; J A Hank; P C Kohler
Journal:  Oncology (Williston Park)       Date:  1987-08       Impact factor: 2.990

3.  Lymphotoxins, macrophage cytotoxins, and tumor necrosis factors: an interrelated family of antitumor effector molecules.

Authors:  G A Granger; S L Orr; R S Yamamoto
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

4.  Recombinant interferon-gamma stimulates the production of human tumor necrosis factor in vitro.

Authors:  P Scuderi; K E Sterling; A B Raitano; T M Grogan; R A Rippe
Journal:  J Interferon Res       Date:  1987-04

5.  Phenotypic and functional analysis of human CD3+ and CD3- clones with "lymphokine-activated killer" (LAK) activity. Frequent occurrence of CD3+ LAK clones which produce interleukin-2.

Authors:  M C Mingari; S Ferrini; D Pende; C Bottino; I Prigione; A Moretta; L Moretta
Journal:  Int J Cancer       Date:  1987-10-15       Impact factor: 7.396

6.  Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells.

Authors:  V Ruggiero; K Latham; C Baglioni
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

7.  The role of asparagine-linked carbohydrate in natural killer cell-mediated cytolysis.

Authors:  P B Ahrens; H Ankel
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

8.  Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.

Authors:  S Ferrini; S Miescher; M R Zocchi; V von Fliedner; A Moretta
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

9.  Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.

Authors:  P M Peters; J R Ortaldo; M R Shalaby; L P Svedersky; G E Nedwin; T S Bringman; P E Hass; B B Aggarwal; R B Herberman; D V Goeddel
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

10.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.

Authors:  E W Jeffes; Y B Beamer; S Jacques; R S Silberman; B Vayuvegula; S Gupta; J S Coss; R S Yamamoto; G A Granger
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

3.  T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: evidence with a single T cell clone.

Authors:  A Mazzocchi; A Anichini; C Castelli; M Sensi; F Poli; C Russo; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Phenotypic analyses of lymphokine-activated killer cells that release interferon gamma and tumor necrosis factor alpha.

Authors:  A S Chong; B Ybarrondo; W J Grimes; E M Hersh; P Scuderi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 5.  Tumour necrosis factor: a cytokine with multiple biological activities.

Authors:  G Semenzato
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

6.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Authors:  German G Gomez; Susana B Read; Lazaro E Gerschenson; Daniela Santoli; Adam Zweifach; Carol A Kruse
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

7.  Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.

Authors:  M Sensi; L Grazioli; M Rodolfo; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients.

Authors:  N Karimine; S Arinaga; H Inoue; S Nanbara; H Ueo; T Akiyoshi
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

9.  Mononuclear phagocytes: a major population of effector cells responsible for rejection of allografted tumor cells in mice.

Authors:  R Yoshida; O Takikawa; T Oku; A Habara-Ohkubo
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

10.  Membrane-associated lymphotoxin expression and functional analysis of lymphokine-activated killer cells derived from tumor-infiltrating lymphocytes.

Authors:  A Horiuchi; Y Abe; M Miyake; K Kimura; Y Hitsumoto; N Takeuchi; S Kimura
Journal:  Jpn J Cancer Res       Date:  1993-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.